# Managing Recurrent Postictal Worsening of Psychosis in Clozapine‐Treated Schizophrenia: A Case Report

**Authors:** Rafae Alam, Robert O. Cotes, David R. Goldsmith

PMC · DOI: 10.1155/crps/8712049 · Case Reports in Psychiatry · 2026-02-23

## TL;DR

A patient with schizophrenia on clozapine experienced worsened psychosis after a seizure, which was managed by temporarily increasing her medication dose.

## Contribution

This case report provides a potential management strategy for postictal worsening of psychosis in clozapine-treated schizophrenia.

## Key findings

- A 49-year-old woman with schizophrenia on clozapine experienced a seizure followed by worsened psychotic symptoms.
- Increasing the clozapine dose at night successfully managed the postictal worsening of psychosis.
- A similar episode occurred a year later, supporting the effectiveness of the management approach.

## Abstract

Postictal worsening of psychosis can be described as the development or exacerbation of psychotic symptoms following a seizure. Patients on clozapine for treatment‐resistant schizophrenia are at an increased risk for seizures and subsequent postictal worsening of psychosis. Because patients with schizophrenia may experience ongoing psychotic symptoms, it may be difficult to appreciate the development of postictal worsening of psychosis in these patients. We present the case of a 49‐year‐old woman with a longstanding history of schizophrenia treated with clozapine who presented to the emergency department (ED) after experiencing a seizure. In the following days, she and her mother reported an exacerbation of psychotic symptoms, which was ultimately attributed to a postictal worsening of psychosis. She was successfully treated after being prescribed an increased nightly dose of clozapine. This dose was eventually reduced to the usual dose she had been taking prior to the postictal exacerbation of psychosis. We also briefly describe a recurrent episode the patient experienced approximately 1 year later. This case contributes to the literature by offering one potential management strategy for postictal worsening of psychosis in a patient with a primary psychotic disorder.

## Linked entities

- **Chemicals:** clozapine (PubChem CID 135398737)
- **Diseases:** schizophrenia (MONDO:0005090)

## Full-text entities

- **Diseases:** irritable (MESH:D001523), insomnia (MESH:D007319), ischemic (MESH:D002545), paranoia (MESH:D010259), Schizophrenia (MESH:D012559), cerebral atrophy (MESH:D001284), headache (MESH:D006261), cerebral dysfunction (MESH:D002547), Seizure (MESH:D012640), tongue trauma (MESH:D014060), status epilepticus (MESH:D013226), focal epilepsy (MESH:D004828), emergency (MESH:D004630), tachycardia (MESH:D013610), delirium (MESH:D003693), acute kidney injury (MESH:D058186), myocarditis (MESH:D009205), Psychosis (MESH:D011618), epilepsy (MESH:D004827), auditory hallucinations (MESH:D006212), hypertension (MESH:D006973), myoclonus (MESH:D009207), neutropenia (MESH:D009503), tonic-clonic movements (MESH:D004830), incontinence (MESH:D014549), manic (MESH:D001714)
- **Chemicals:** lactate (MESH:D019344), Clozapine (MESH:D003024), acetaminophen (MESH:D000082), ammonia (MESH:D000641), Lamotrigine (MESH:D000077213), Sodium valproate (MESH:D014635), zonisamide (MESH:D000078305), salicylate (MESH:D012459), ASM (-), alcohol (MESH:D000438), Topiramate (MESH:D000077236), vigabatrin (MESH:D020888), mirabegron (MESH:C520025), gabapentin (MESH:D000077206), lacosamide (MESH:D000078334), levetiracetam (MESH:D000077287), solifenacin (MESH:D000069464)
- **Species:** Canis lupus familiaris (dog, subspecies) [taxon 9615], Nicotiana tabacum (American tobacco, species) [taxon 4097], Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12927945/full.md

## References

23 references — full list in the complete paper: https://tomesphere.com/paper/PMC12927945/full.md

---
Source: https://tomesphere.com/paper/PMC12927945